Go Pro
→ Trump Takes Emergency Action - Plus Elon Musk's New Venture (From Altimetry) (Ad)tc pixel
OTCMKTS:HYPMY

Hypermarcas Q4 2025 Earnings Report

Hypermarcas logo
$4.13 -0.03 (-0.78%)
As of 03:36 PM Eastern
ProfileEarnings HistoryForecast

Hypermarcas EPS Results

Actual EPS
$0.13
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Hypermarcas Revenue Results

Actual Revenue
$414.22 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Hypermarcas Announcement Details

Quarter
Q4 2025
Date
3/12/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Hypermarcas' next earnings date is estimated for Thursday, August 6, 2026, based on past reporting schedules.

Conference Call Resources

Hypermarcas Earnings Headlines

Hypera SA ADR (HYPMY)
May 24, 2026  |  investing.comhttps://www.investing.com/equities/hypermarcas-sa-financial-summary
Hypera S.A. (HYPMY) Q3 2025 Earnings Call Transcript
October 29, 2025  |  seekingalpha.comhttps://seekingalpha.com/article/4834950-hypera-s-a-hypmy-q3-2025-earnings-call-transcript
The dollar reset no one told you about
Porter Stansberry says a dollar reset is underway - one that has happened only once before in America's 250-year history, back in 1974 with a secret Saudi deal that reshaped an entire generation's wealth. Today, a landmark treaty called Pax Silica - signed by 13 nations in December 2025 and barely covered in the press - is at the center of what Fortune calls 'the biggest change to the world's relationship with the dollar' in a generation. The stocks to buy, the assets to avoid, and the moves to consider are outlined in Stansberry's new briefing.tc pixel
August 6 at 1:00 AM  |  Porter & Company (Ad)
Brazil's Hypera announces new majority stakeholder group
July 7, 2025  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/brazils-hypera-announces-new-majority-stakeholder-group-2025-07-07/
Hypera S.A. (HYPMY) Stock Price, Quote, News & Analysis - Seeking Alpha
June 29, 2025  |  seekingalpha.comhttps://seekingalpha.com/symbol/HYPMY
Hypera S.A. credit rating downgraded due to increased leverage
April 9, 2025  |  investing.comhttps://www.investing.com/news/stock-market-news/hypera-sa-credit-rating-downgraded-due-to-increased-leverage-93CH-3977909
See More Hypermarcas Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Hypermarcas? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Hypermarcas and other key companies, straight to your email.

About Hypermarcas

Hypermarcas (OTCMKTS:HYPMY) S.A. is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.

Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products. Its pharmaceutical lineup includes analgesics, anti-inflammatories, vitamins and dermatological preparations, while its consumer goods segment encompasses shampoos, soaps, lotions and oral hygiene items under multiple local brands.

Primarily focused on the domestic Brazilian market, Hypermarcas has also extended its reach into other Latin American countries via export partnerships and regional distributors. Over the years, the company has grown through acquisitions of smaller domestic drugmakers and consolidation of well-known local brands. Detailed executive leadership information is not widely available in public sources.

View Hypermarcas Profile
Earnings Tools